{"name": "VasoGenix",
 "permalink": "vasogenix",
 "crunchbase_url": "http://www.crunchbase.com/company/vasogenix",
 "homepage_url": "http://www.vasogenix.net",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": null,
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "(913) 888-4773",
 "description": "",
 "created_at": "Sat Apr 18 12:01:18 UTC 2009",
 "updated_at": "Sat May 09 22:06:20 UTC 2009",
 "overview": "\u003Cp\u003EVasoGenix Pharmaceuticals, Inc., is developing intravenous (IV) and controlled release drug treatments for addressing Heart Failure (\u0026#8220;HF\u0026#8221;) and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs. VasoGenix is initially focusing on a major unmet critical need in Acute Decompensated Heart Failure (\u0026#8220;ADHF\u0026#8221;), when the symptoms of HF become severe enough to require hospitalization.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       44],
      "assets/images/resized/0004/1820/41820v1-max-150x150.png"],
     [[250,
       74],
      "assets/images/resized/0004/1820/41820v1-max-250x250.png"],
     [[341,
       102],
      "assets/images/resized/0004/1820/41820v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$400k",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.forbes.com/feeds/businesswire/2009/01/29/businesswire119764484.html",
    "source_description": "VasoGenix Pharmaceuticals Awarded $400,000 by Kansas Bioscience Authority to Continue...",
    "raised_amount": 400000.0,
    "raised_currency_code": "USD",
    "funded_year": null,
    "funded_month": null,
    "funded_day": null,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Kansas Bioscience Authority",
         "permalink": "kansas-bioscience-authority",
         "image":
          {"available_sizes":
            [[[150,
               58],
              "assets/images/resized/0006/2294/62294v2-max-150x150.png"],
             [[250,
               98],
              "assets/images/resized/0006/2294/62294v2-max-250x250.png"],
             [[298,
               117],
              "assets/images/resized/0006/2294/62294v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "VasoGenix Pharma",
    "address1": "8527 Bluejacket Street",
    "address2": "",
    "zip_code": "66214",
    "city": "Lenexa",
    "state_code": "KS",
    "country_code": "USA",
    "latitude": 38.974099,
    "longitude": -94.710676}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        95],
       "assets/images/resized/0004/3575/43575v1-max-150x150.jpg"],
      [[250,
        159],
       "assets/images/resized/0004/3575/43575v1-max-250x250.jpg"],
      [[450,
        286],
       "assets/images/resized/0004/3575/43575v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}